This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Delving into the results from OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema

Ticker(s): IONS

Who's the expert?

Institution: Corewell Health

  • Cheif of Allergy and Immunology at Corewell Health in both pediatric and adult sections.
  • Treats 60 patients refractory to antihistamines with mod-sev CSU
  • Clinical clinical interests in allergy & immunology including chronic spontaneous urticaria, hereditary angioedema, food allergy, severe asthma, bee sting allergy and drug allergy.
  • paid lit review of these slides attached

Interview Goal
to discuss the current standard of care and the potential of donidalorsen, an investigative prophylactic medicine being developed by Ionis Pharma to prevent HAE attacks.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.